Potential future targets for treating ocular neovascularization.

A wide variety of mediators likely contribute to ocular NV and these can serve as potential targets for the treatment of ocular NV. Several targets have already been validated in preclinical models and are being explored in clinical studies. In addition, targeting other processes besides angiogenesis, such as inflammation and apoptosis, may be beneficial in the treatment of ocular NV. Combined approaches with the use of several angiogenesis inhibitors or anti-inflammatory agents may show synergistic effects in treating ocular NV.

• Publication year

  2006

• Venue

  Ophthalmology Clinics of North America

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.OHC.2006.05.004PMID 16935215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different effects of angiopoietin‐2 in different vascular beds in the eye: new vessels are most sensitive

  2005cited by this paper
• Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.

  2005cited by this paper
• Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B.

  2005cited by this paper
• Genistein inhibited hypoxia-inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells.

  2005cited by this paper
• Physiological role of collagen XVIII and endostatin

  2005cited by this paper
• Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier

  2004cited by this paper
• Angiopoietins in tumours: the angiogenic switch

  2004cited by this paper
• Pegaptanib for neovascular age-related macular degeneration.

  2004cited by this paper
• Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor

  2004cited by this paper
• The effect of angiostatin on vascular leakage and VEGF expression in rat retina

  2004cited by this paper
• Ocular neovascularization: a valuable model system

  2003cited by this paper
• VEGF‐TRAPR1R2 suppresses choroidal neovascularization and VEGF‐induced breakdown of the blood–retinal barrier

  2003cited by this paper
• MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization

  2003cited by this paper
• Molecular basis of angiogenesis and cancer

  2003cited by this paper
• Blockade of nitric-oxide synthase reduces choroidal neovascularization.

  2002cited by this paper
• A reevaluation of integrins as regulators of angiogenesis

  2002cited by this paper
• AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.

  2002cited by this paper
• Nitric oxide is proangiogenic in the retina and choroid *

  2002cited by this paper
• Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury

  2002cited by this paper
• Matrix metalloproteinase-9 contributes to choroidal neovascularization.

  2002cited by this paper
• Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor.

  2002cited by this paper
• Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment.

  2002cited by this paper
• Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.

  2002cited by this paper
• Antiangiogenesis agents.

  2002cited by this paper
• Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1–3 of angiostatin reduce retinal neovascularization

  2002cited by this paper
• Erythropoietin and VEGF exhibit equal angiogenic potential.

  2002cited by this paper
• HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration

  2002cited by this paper
• Suppression of diabetic retinopathy with angiopoietin-1.

  2002cited by this paper
• Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization

  2001cited by this paper
• Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.

  2001cited by this paper
• Evaluation of Intraocular Pharmacokinetics and Toxicity of Prinomastat (AG3340) in the Rabbit

  2001cited by this paper
• Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin.

  2001cited by this paper
• Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.

  2001cited by this paper
• Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).

  2001cited by this paper
• Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells.

  2000cited by this paper
• VEGF is major stimulator in model of choroidal neovascularization.

  2000cited by this paper
• AG-3340 (Agouron Pharmaceuticals Inc).

  2000cited by this paper
• Vitaxin applied molecular evolution.

  2000cited by this paper
• AG-3340 (Agouron Pharmaceuticals Inc).

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.

  1999cited by this paper
• Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

  1999cited by this paper
• Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.

  1999cited by this paper
• Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

  1999cited by this paper
• Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.

  1999cited by this paper
• Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

  1999cited by this paper
• Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.

  1998cited by this paper
• Increased vascularization in mice overexpressing angiopoietin-1.

  1998cited by this paper
• Matrix metalloproteinases and their inhibitors in human vitreous.

  1998cited by this paper
• Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization.

  1998cited by this paper
• Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.

  1998cited by this paper
• Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and Primates

  1997cited by this paper
• Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

  1997cited by this paper
• Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

  1997cited by this paper
• Essential role of growth hormone in ischemia-induced retinal neovascularization.

  1997cited by this paper
• Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

  1996cited by this paper
• Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

  1996cited by this paper
• Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome.

  1995cited by this paper
• Growth factor localization in choroidal neovascular membranes of age-related macular degeneration.

  1994cited by this paper
• Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

  1994cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.

  1990cited by this paper
• Metastatic potential correlates with enzymatic degradation of basement membrane collagen

  1980cited by this paper
• Serum Growth Hormone Levels and the Response of Diabetic Retinopathy to Pituitary Ablation*

  1969cited by this paper
• The Houssay Phenomenon in Man: Recovery from Retinopathy in a Case of Diabetes With Simmonds' Disease

  1953cited by this paper

• 21 Limbal Stem Cell Transplantation and Corneal Neovascularization

  2017cites this paper
• Limbal Stem Cell Transplantation and Corneal Neovascularization

  2012cites this paper
• Intraocular expression of thymosin β4 in proliferative diabetic retinopathy

  2011cites this paper
• Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications

  2010cites this paper
• Review of the Ocular Angiogenesis Animal Models

  2009cites this paper
• Intraocular pharmacotherapy: specificity and safety issues

  2007cites this paper